Optimal CAB Case Study: Pediatric Dolutegravir
This case study, developed by the Optimal CAB in Malawi with support from CHAI, outlines the efforts undertaken by Malawi CAB members to...
top of page
A framework to support new product introduction in national health systems
Resource Library
- May 16
CAB Case Studies from Ethiopia
These Community Advisory Board (CAB) case studies capture highlights of what CAB members considered to be some of the most impactful...
34
- Feb 27
Community Statements on DRV/r Use in 2L
In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global...
36
- Feb 16
CAB Case Studies from Tanzania
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
26
- Feb 16
CAB Case Studies from Zambia
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
19
- Feb 16
CAB Case Studies from Nigeria
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
30
- Feb 16
CAB Case Studies from Uganda
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
26
- Oct 18, 2022
Prevention Product Preference Brief
New products, including long-acting formulations, will be critical to achieve HIV treatment and prevention targets and close gaps among...
32
- Oct 18, 2022
CAB-LA Community Meeting Overview
A Community Forum: Supporting Affordable Access to Long-Acting Injectable Cabotegravir (CAB-LA) took place in Kampala, Uganda from June...
47
- Sep 12, 2022
AHD Community Advocacy Video
This video was developed by Community Advisory Board (CAB) members, and is intended to increase awareness and utilization of services for...
92
- Sep 12, 2022
Pediatric DTG Advocacy Video for Communities (English and French)
This advocacy video provides a brief overview of pDTG to encourage demand generation for the product. The video is available at the...
182
- Jul 31, 2022
Optimal CAB Case Study: Enabling and Ensuring Equitable HIV Treatment for Women
This case study, developed by the Optimal CAB with support from CHAI, outlines the mobilization of community members in response to the...
5
- Jul 31, 2022
Case Study: Community-Developed HIV Care and Treatment Literacy Improves Uptake of Optimal Medicines
This case study, developed by the Optimal CAB with support from CHAI, outlines the tremendous work done by community members developing...
6
- Jun 16, 2022
AHD Social Media Campaign
These resources, developed by Community Advisory Board (CAB) members, are intended to increase awareness and utilization of services for...
165
- Apr 27, 2022
Pediatric DTG Administration Video for Caregivers (English and French)
This video demonstrates to parents and caregivers how to administer pDTG to their children, including dosing amounts by weight. This...
167
- Apr 13, 2022
Adult DRV/r (400/50mg) FAQs for Communities and PLHIV
CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...
157
- Apr 4, 2022
Pediatric DTG Poster (English, French, Swahili)
A poster to encourage demand generation for pDTG that may be used for distribution to communities and caregivers, or for display in...
105
- Apr 4, 2022
Pediatric DTG FAQs for Caregivers and Communities (English, French, Swahili)
This document provides in-depth information on pDTG and answers to frequently asked questions for caregivers and communities to better...
103
- Apr 4, 2022
Pediatric DTG Administration Poster for Caregivers (English, French, Swahili)
This poster provides caregivers with information on dosing and administration of pDTG to children. (English | French | Swahili)
209
- Apr 4, 2022
Pediatric DTG Pocketbook for Caregivers (English, French, Swahili)
This easily accessible pocketbook provides key information on pDTG, including benefits, eligibility, dosing, administration, and side...
98
bottom of page